共 50 条
- [1] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Burotto, MauricioPowles, ThomasEscudier, BernardApolo, Andrea B.Bourlon, Maria TeresaShah, Amishi YogeshSuarez, CristinaPorta, CamilloBarrios, Carlos H.Richardet, MartinGurney, HowardKessler, Elizabeth R.Tomita, YoshihikoBedke, JensGeorge, SabyScheffold, ChristianWang, PeterFedorov, ViktorMotzer, Robert J.Choueiri, Toni K.
- [2] Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialESMO OPEN, 2024, 9 (05)Powles, T.Burotto, M.Escudier, B.Apolo, A. B.Bourlon, M. T.Shah, A. Y.Suarez, C.Porta, C.Barrios, C. H.Richardet, M.Gurney, H.Kessler, E. R.Tomita, Y.Bedke, J.George, S.Scheffold, C.Wang, P.Fedorov, V.Motzer, R. J.Choueiri, T. K.
- [3] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trialANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159Choueiri, T. K.Powles, T.Burotto, M.Bourlon, M. T.Zurawski, B.Oyervides Juarez, V. M.Hsieh, J. J.Basso, U.Shah, A. Y.Suarez, C.Hamzaj, A.Barrios, C. H.Richardet, M.Pook, D.Tomita, Y.Escudier, B.Zhang, J.Simsek, B.Apolo, A. B.Motzer, R. J.
- [4] Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Choueiri, Toni K.Motzer, Robert J.Powles, ThomasBurotto, MauricioApolo, Andrea B.Escudier, BernardMcDermott, David F.Braun, David A.Han, CelineLee, GeorgeDwivedi, BhaktiLi, JunGupta, Saurabh
- [5] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinomaCancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189Benjamin Duy TranJing LiNeang LyRaffaella FaggioniLorin Roskos
- [6] First-line nivolumab plus cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trialANNALS OF ONCOLOGY, 2021, 32 : S688 - S689Porta, C. G.Burotto, M.Suarez Rodriguez, C.Bourlon, M. T.Hsieh, J.Shah, A. Y.Hamzaj, A.Bedke, J.Pook, D.Kessler, R.Tomita, Y.Drakaki, A.Zhang, J.Simsek, B.Schwab, G.Escudier, B.Motzer, R. J.Choueiri, T. K.Apolo, A. B.Powles, T. B.
- [7] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinomaCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189Tran, Benjamin DuyLi, JingLy, NeangFaggioni, RaffaellaRoskos, Lorin
- [8] Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 363 - 363Escudier, BernardMcdermott, David F.Burotto, MauricioChoueiri, Toni K.Hammers, Hans J.Plimack, Elizabeth R.Porta, CamilloGeorge, SabyPowles, ThomasDonskov, FredeAtkins, Michael B.Kollmannsberger, Christian K.Grimm, Marc-OliverTomita, YoshihikoRini, Brian I.Jiang, RuiyunDesilva, HeshaniLee, Chung-WeiMotzer, Robert J.
- [9] Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trialASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 131 - 131Pook, DavidPowles, ThomasBurotto, MauricioBourlon, Maria T.Hsieh, James J.Basso, UmbertoShah, Amishi Y.Suarez, CristinaPorta, CamilloBarrios, CarlosGurney, HowardKessler, Elizabeth R.Retz, MargittaGeorge, SabyEscudier, BernardZhang, JoshuaSimsek, BurcinScheffold, ChristianMotzer, Robert J.Choueiri, Toni K.Apolo, Andrea B.
- [10] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2022, 23 (07): : 888 - 898Motzer, Robert J.Powles, ThomasBurotto, MauricioEscudier, BernardBourlon, Maria T.Shah, Amishi Y.Suarez, CristinaHamzaj, AlketaPorta, CamilloHocking, Christopher M.Kessler, Elizabeth R.Gurney, HowardTomita, YoshihikoBedke, JensZhang, JoshuaSimsek, BurcinScheffold, ChristianApolo, Andrea B.Choueiri, Toni K.